BGE-102InterventionPhase 21 paperDevelopmentCompaniesBioAge LabsPhase 2Sep 2026cardiovascular risk, diabetic macular oedemaLatestNov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 0Oct 2026: 01 in 12 monthsBiochemical Pharmacology·22 AugImmunopharmacological reprogramming of innate immune memory in Alzheimer's disease: From microglial priming to therapeutic resilienceReviewAlzheimer's diseasePaper
Biochemical Pharmacology·22 AugImmunopharmacological reprogramming of innate immune memory in Alzheimer's disease: From microglial priming to therapeutic resilienceReviewAlzheimer's diseasePaper